A Major Unmet Need in a Rapidly Growing Market
Infertility continues to be a high-need area in reproductive health with limited improvement in implantation success rates over recent decades.
-
IVF success rates remain low at ~35%
-
Up to 20% of women face unexplained recurrent implantation failure
-
Most IVF research to date has focused on embryo optimisation
-
The uterine environment remains a limiting factor
Impaired lymphatic function in the endometrium is believed to contribute to implantation challenges and remains under active investigation.
Vessely™ : Restoring Implantation Capability
Vessely™ is LYMPHOGENiX’s proprietary product candidate, currently in preclinical development, designed to modulate lymphatic pathways within the uterine microenvironment.
Unlocking the Endometrium’s Lymphatic Network
Vessely™ is designed to restore the lymphatic system within the endometrium — a critical regulator of immune balance, fluid homeostasis, and tissue stability during implantation. By regenerating functional lymphatic vessels, Vessely™ helps re-establish a uterine environment capable of supporting stable embryo attachment and early pregnancy.
Robust and Reproducible Restoration of Implantation
Pre-clinical data suggests that modulation of lymphatic networks is associated with biological changes relevant to implantation pathways.
Severe Infertility Model (IUA)
Animal models are used for translational feasibility assessment; findings remain preliminary.
One-Sided Infertility
Implantation restored exclusively in treated uterine tissue, demonstrating localized biological effect.
Reproducibility
Preliminary outcomes observed in repeat studies; results are under further evaluation.
Cows as a Translational Bridge from Mice to Humans
We plan to use cows as a translational research model because their
reproductive anatomy more closely resembles the human reproductive
system.
Our bovine studies will allow the exploration of dosing parameters,
manufacturing considerations, and translational study design.
We will conduct these studies under ethical, non-lethal conditions and
aim to generate preliminary translational insights relevant to human
reproductive biology.
Science & Platform
This is where investors see the depth, legitimacy, and future potential of your technology. It’s credibility-heavy but should remain readable, paragraph-style, and confidence-building.
-
LYMPHOGENiX has engaged in foundational research into lymphatic biology over the last 15+ years with multiple peer-reviewed publications.
-
At the core of LYMPHOGENiX is a robust regenerative platform with demonstrated efficacy in cardiac and pulmonary indications.
-
While infertility is our lead clinical programme, our technology has potential in other areas such as fibrosis, skin aging, and metabolic disorders.
Science Overview:
LYMPHOGENiX has engaged in foundational research into lymphatic biology, with peer-reviewed publications and patents supporting ongoing preclinical programmes.
Platform & Pipeline:
At the core of LYMPHOGENiX is a robust regenerative platform capable of developing therapies across multiple indications. While infertility remains our primary focus, our technology holds potential in areas such as fibrosis, skin aging, and metabolic disorders. Each opportunity is approached with discipline, ensuring that current focus is never diluted while positioning the company for future growth.
Invest in LYMPHOGENiX
LYMPHOGENiX is raising $5M to advance Vessely™ through preclinical development, CMC optimization, and regulatory preparation for First-in-Human trials. These funds will accelerate our path toward clinical translation, ensuring readiness for a successful human study in 2027.
Over the next two years, we will complete GLP studies, finalize manufacturing processes, and prepare regulatory submissions. This disciplined approach de-risks the transition from preclinical research to clinical application.
Our strategy is focused on strategic licensing or acquisition by a leading IVF pharmaceutical company, offering investors a clear and attainable path to value realization.
15+ years R&D ✦ 6 international patents ✦ First-in-Human planned (2028) ✦
